Sarepta Therapeutics

-$6.20 (-4.3%)
Closing price September 24, 2020
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Here are the biotech companies with exposure to experimental vaccines whose shares saw the biggest boost from this past week's coronavirus news.
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this...
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Friday's top analyst upgrades, downgrades and initiations included Arista Networks, Booking, Dunkin' Brands, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square and YETI.
Sarepta shares jumped on Friday after the firm announced an update from its Duchenne muscular dystrophy trial.
One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the biotech companies. The four top stocks have gigantic implied upside.
Tuesday was a breakout day for a few biotech companies that saw either huge gains or massive losses. 24/7 Wall St. has picked a few of those standouts to highlight.
The included AbbVie, Beyond Meat, Bio-Rad Laboratories, Dell Technologies, HP, Jumia Technologies, Nabriva Therapeutics, PG&E, and Sarepta Therapeutics.
With the market clearly close to, or at full value, it makes sense to look to areas where alpha can be generated for the rest of 2019. These five top stocks are the best picks from the Merrill team...